Lipid-Lowering Agent Use at Ischemic Stroke Onset is Associated with Decreased Mortality
Neurol 65:253-258, Elkind,M.S.V.,et al, 2005
Guidelines for the Early Management of Patients with Ischemic Stroke
Stroke 34:1056-1083, Adams,H.P.,et al, 2003
Calcium Antagonists for Ischemic Stroke
Stroke 32:570-576, Horn,J. &Limburg,M., 2001
Combating Hyperthermia in Acute Stroke, A Significant Clinical Concern
Stroke 29:529-534, Ginsberg,M.D.&Busto,R., 1998
Further Evolution Toward Effective Therapy for Acute Ischemic Stroke
JAMA 279:1298-1303, 13041998., Fisher,M.&Bogousslavsky,J., 1998
Lubeluzole Treatment of Acute Ischemic Stroke
Stroke 28:2338-2346, Grotta,J., 1997
Lubeluzole in Acute Ischemic Stroke:A Double-Blind Placebo-Controlled Phase II Trial
Stroke 27:76-81, Diener,H.C.,et al, 1996
Comparison of Therapeutic Effects & Mortality Data of Levodopa & Levodopa with Selegiline in Pts with Early, Mild Parkinson's
BMJ 311:1602-1607, 15831995., Lee,A.J.,et al, 1995
A Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine in Acute Ischemic Hemispheric Stroke
Stroke 25:1348-1353, Kaste,M.,et al, 1994
Guidelines for the Management of Patients with Acute Ischemic Stroke
Stroke 25:1901-1914, Adams,H.P.,et al, 1994
Restorative Neurology, Drugs and Recovery Following Stroke
Stroke 21:1636-1640, Goldstein,L.B.&Davis,J.N., 1990
Evolving Toward Effective Therapy for Acute Ischemic Stroke
JAMA 270:360-364, Fisher,M.&Bogousslavsky,J., 1993
Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 383:2213-2221, Chataway, J.,et al, 2014
Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008
Diagnosis and Management of Motor Neurone Disease
BMJ 336:658-662, McDermott,C.J. &Shaw,P.J., 2008
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Therapeutic Hypothermia for Global and Focal Ischemic Brain Injury-A Cool Way to Improve Neurologic Outcomes
Neurologist 13:331-342, Hoesch,R.E. &Geocadin,R., 2007
Piracetam for Acute Ischemic Stroke
Stroke 37:2191-2192, Ricci,S.,et al, 2006
Guidelines for the Early Management of Patients with Ischemic Stroke
Stroke 36:916-921, Adams,H.,et al, 2005
Statins Are Associated With Better Outcomes After Carotid Endarterectomy in Symptomatic Patients
Stroke 36:2072-2076,2058, Kennedy,J.,et al, 2005
Magnesium for Acute Stroke (Intravenous Magnesium Efficacy in Stroke Trial):Randomised Controlled Trial
Lancet 363:439-445,414, Goldstein,L.B., 2004
Prognostic Significance of Uric Acid Serum Concentration in Patients with Acute Ischemic Stroke
Stroke 33:1048-1052, Chamorro,A.,et al, 2002
Human Albumin Therapy of Acute Ischemic Stroke
Stroke 32:553-560, Belayev,L.,et al, 2001
Cooling for Acute Ischemic Brain Damage (COOL AID)
Stroke 32:1847-1854, Krieger,D.W.,et al, 2001
New Imaging Strategies for Patient Selection for Thrombolytic and Neuroprotective Therapies
Neurol 57:S48-S52, Warach,S., 2001
Aptiganel Hydrochloride in Acute Ischemic Stroke
JAMA 286:2673-2682,2718, Albers,G.W.,et al, 2001
HMG-CoA Reductase Inhibitors (Statins)
Neurol 54:790-795, Hess,D.C.,et al, 2000
Reduced Prevalence of AD in Users of NSAIDs and H2 Receptor Antagonists
Neurol 54:2066-2071, Anthony,J.C.,et al, 2000
Ischemic Core and Penumbra in Human Stroke
Stroke 30:93-99, Kaufmann,A.M.,et al, 1999
Neuroprotective Properties of Statins in Cerebral Ischemia and Stroke
Stroke 30:1969-1973, Vaughan,C.J.&Delanty,N., 1999
Duration of Neuroprotective Treatment for Ischemic Stroke
Stroke 29:535-542, Dyker,A.G.&Lees,K.R., 1998
Morality in DATATOP:A Multicenter Trial in Early Parkinson's Disease
Parkinson Study Group, Ann Neurol 43:318-3251998., , 1998
Progression of Ischaemic Stroke and Excitotoxic Aminoacids
Lancet 349:79-83, Castillo,J.,et al, 1997
Characterizing the Target of Acute Stroke Therapy
Stroke 28:866-872, Fisher,M., 1997
Treatment of Acute Ischemic Stroke with Piracetam
Stroke 28:2347-2352, DeDeyn,P.P.,et al, 1997
Cognitive Impairment & Mortality in a Cohort of Elderly People
BMJ 312:608-611, Gale,C.R.,et al, 1996
Selegiline and Mortality in Parkinson's Disease
Ann Neurol 40:841-845, Olanow,C.W.,et al, 1996
Clinical Experience with Excitatory Amino Acid Antagonist Drugs
Stroke 26:503-513, Muir,K.W.&Lees,K.R., 1995
Head Injury
JNNP 58:526-539, Teasdale,G.M., 1995
The Ischemic Penumbra, Injury Thresholds, and the Therapeutic Window for Acute Stroke
Ann Neurol 36:553-554, 5571994., Ginsberg,M.D.&Pulsinelli,W.A., 1994
Head Injury
JNNP 56:440-447, Miller,J.D., 1993
Clinical Trial of Nimodipine in Acute Ischemic Stroke
The American Nimodipine Study Group, Stroke 23:3-81992., , 1992
Pathophysiology of Acute Ischaemic Stroke
Lancet 339:533-536, Pulsinelli,W., 1992
Serum Concentrations of Vitamins A and E and Early Outcome after Ischaemic Stroke
Lancet 339:1562-1565, DeKeyser,J.,et al, 1992
Do NMDA Antagonists Prevent Neuronal Injury? Yes
ARch Neurol 49:418-420, Albers,G.W.,et al, 1992
Do NMDA Antagonists Prevent Neuronal Injury? No
Arch Neurol 49:420-421, Buchan,A.M., 1992
Early Treatment of Ischemic Stroke with a Calcium Antagonist
Stroke 22:437-441, Rosenbaum,D.,et al, 1991
Tissue Plasminogen Activator Plus Glutamate Antagonist Improves Outcome after Embolic Stroke
Arch Neurol 48:1235-1238, Zivin,J.A.&Mazzarella,V., 1991
The Bioloigcal Basis for the Treatment of Acute Stroke
Neurol 41:1867-1873, Scheinberg,P., 1991